Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25

Articles

19310 items
12:00 AM, May 24, 1993  |  BioCentury | Strategy

The $8.5 million difference

The $8.5 million difference Less than two years after telling start-up GeneSys Therapeutics Corp. that it should seek a merger partner because of a glut of gene therapy companies, Kleiner Perkins Caufield & Byers is...
12:00 AM, May 17, 1993  |  BioCentury | Politics, Policy & Law

Controlling demand

Controlling demand The national debate on health care has taken as a given the premise that the United States is spending an excessive proportion of its gross domestic product on health care. So when Stephen Lurito,...
12:00 AM, May 17, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Nomura Research Institute America Nomura Research Institute America analyst Robert Fine initiated coverage of Genentech Inc. with a "buy" rating. Among the reasons he cited: if Roche exercises its buyout option the minimum return...
12:00 AM, May 17, 1993  |  BioCentury | Strategy

Sphinx cuts a new deal with Lilly

Sphinx cuts a new deal with Lilly The latest company to retrieve some of its technology is Sphinx Pharmaceuticals Corp., which on Friday said it restructured its agreement with Eli Lilly and Co. covering...
12:00 AM, May 17, 1993  |  BioCentury | Strategy

When the product comes back

When the product comes back Many biotech companies give away their babies. Whether because they need cash, or because they need the marketing clout of a bigger company, or to gain the validation on Wall...
12:00 AM, May 10, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Univax Biologics Inc. Joseph Edelman of Prudential Securities raised Univax Biologics Inc. to "buy" from "hold," citing upcoming events as improving near-term prospects for the stock. He expects UNVX to file a PLA for its ...
12:00 AM, May 10, 1993  |  BioCentury | Product Development

NIAID launches vaccine trials

NIAID launches vaccine trials The National Institute of Allergy and Infectious Diseases has begun the first clinical trials of therapeutic AIDS vaccine candidates in pregnant women with HIV infection, using the Genentech Inc. gp120...
12:00 AM, May 10, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

CytoTherapeutics Inc. Hancock Institutional Equity Services analyst Margaret McGeorge initiated coverage of CytoTherapeutics Inc. with a "speculative buy" recommendation. McGeorge said that at its current valuation of $55 million, the risk-reward ratio is favorable. CTII is...
12:00 AM, May 10, 1993  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Biogen Inc. (BGEN) Joseph Edelman of Prudential Securities downgraded Biogen Inc. (BGEN) on a price basis to "hold" from "buy." The stock was approaching his 52-week price target of $38 and has outperformed the group...
12:00 AM, May 10, 1993  |  BioCentury | Politics, Policy & Law

Durbin responds

Durbin responds I would like to share with your subscribers a further examination of the impact of my Prescription Drug Consumer Protection Act of 1993 on the biotechnology industry. My legislation does not make explicit distinctions...

Pages